The data for the CD4+, CD8+, and FOXP3+ TILs and PD-L1+ immune cells were adopted from our previous studies11 (link),36 (link) for 288 cases of DCIS and 339 cases of IBC. Immunohistochemical staining had been performed with a BenchMark XT autostainer (Ventana Medical Systems) using an UltraView detection kit (Ventana Medical Systems). The following antibodies were used: CD4 (clone SP35; ready to use; Dako), CD8 (clone C8/144B; ready to use; Dako), FOXP3 (clone 236A/E7; 1:100; Abcam) and PD-L1 (clone E1L3N; 1:100; Cell Signaling, Danvers, MA, USA).
CD4+, CD8+, and FOXP3+ T cells had been counted in intratumoral and stromal areas as absolute numbers per high-power field. Detailed information on the counting method of TILs is described in the previous studies11 (link),36 (link). PD-L1+ immune cells were considered to be present when at least 1% of the tumor stromal area was occupied by PD-L1+ immune cells.
CD4+, CD8+, and FOXP3+ T cells had been counted in intratumoral and stromal areas as absolute numbers per high-power field. Detailed information on the counting method of TILs is described in the previous studies11 (link),36 (link). PD-L1+ immune cells were considered to be present when at least 1% of the tumor stromal area was occupied by PD-L1+ immune cells.
Free full text: Click here
